Regulatory ApprovalFormycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® 15.01.2025 / 06:30 CET/CESTThe issuer is solely responsible for the ...

Psychological resilience plays an important role in managing psoriasis symptoms and enhancing patient well-being, study ...

Biocon shares rose 9% to ₹389, driven by positive developments including Japanese approval for its biosimilar Ustekinumab.

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...

Biocon Biologics had entered into a settlement and licensing agreement with Janssen Biotech Inc. and Janssen Sciences Ireland ...

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

Biocon added 3.69% to Rs 371.85 after the company said that Biocon Biologics has received approval from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for Ustekinumab BS subcutaneous ...

KBLP-001 is under clinical development by KoBioLabs and currently in Phase II for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase II drugs for Plaque Psoriasis (Psoriasis ...

Research has found a connection between psoriasis and dental health problems. The exact connection is complex but seems to be related to chronic inflammation. Psoriasis is a complicated disease ...

Many cases of mild to moderate psoriasis may be treatable with topical medication. The effectiveness of these treatments varies from person to person, depending on the severity of their psoriasis ...

Issues to be addressed when evaluating a patient for pemphigus include the age of onset, previous clinical symtoms, initial presentation, presence of mucous membrane symptoms and the presence of ...

Ustekinumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Pre-Registration drugs ...